Alector Inc
NASDAQ:ALEC
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
3.94
8.39
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ALEC stock under the Base Case scenario is 6.06 USD. Compared to the current market price of 5.06 USD, Alector Inc is Undervalued by 17%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Alector Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ALEC cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Alector Inc
Balance Sheet Decomposition
Alector Inc
Current Assets | 469.4m |
Cash & Short-Term Investments | 457.2m |
Other Current Assets | 12.2m |
Non-Current Assets | 46.7m |
PP&E | 39m |
Other Non-Current Assets | 7.6m |
Current Liabilities | 142.5m |
Accounts Payable | 5m |
Accrued Liabilities | 37.8m |
Other Current Liabilities | 99.8m |
Non-Current Liabilities | 254.6m |
Other Non-Current Liabilities | 254.6m |
Earnings Waterfall
Alector Inc
Revenue
|
61.5m
USD
|
Operating Expenses
|
-244.5m
USD
|
Operating Income
|
-183m
USD
|
Other Expenses
|
24.6m
USD
|
Net Income
|
-158.4m
USD
|
Free Cash Flow Analysis
Alector Inc
USD | |
Free Cash Flow | USD |
Alector is set for transformative advancements with anticipated key trial readouts. The AL002 Phase II trial for early Alzheimer’s disease will deliver data in Q4 2024, focusing on its TREM2 agonist. Additionally, the FDA has granted breakthrough therapy designation to latozinemab for frontotemporal dementia, with a pivotal Phase III readout expected in late 2025 or early 2026. Financially, Alector ended the quarter with $503.3 million in cash, ensuring operations through 2026. The company also projects collaboration revenue between $60 million and $70 million for 2024. Its proprietary Alector Brain Carrier platform continues to enhance drug delivery capabilities.
What is Earnings Call?
ALEC Profitability Score
Profitability Due Diligence
Alector Inc's profitability score is 9/100. The higher the profitability score, the more profitable the company is.
Score
Alector Inc's profitability score is 9/100. The higher the profitability score, the more profitable the company is.
ALEC Solvency Score
Solvency Due Diligence
Alector Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Score
Alector Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALEC Price Targets Summary
Alector Inc
According to Wall Street analysts, the average 1-year price target for ALEC is 14.03 USD with a low forecast of 4.04 USD and a high forecast of 36.75 USD.
Dividends
Current shareholder yield for ALEC is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. The company is headquartered in South San Francisco, California and currently employs 208 full-time employees. The company went IPO on 2019-02-07. The firm is focused on immuno-neurology, a therapeutic approach for the treatment of neurodegeneration. The firm is engaged in developing therapies designed to counteract these pathologies by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. The firm has advanced four product candidates, AL001, AL002, AL003, and AL101, into clinical development. Its first product candidate, AL001, is a humanized recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of frontotemporal dementia carrying a progranulin (FTD-GRN) patients. Its AL002 targets triggering receptor expressed on myeloid cells 2 (TREM2) to increase the functionality of TREM2 signaling and enhance microglia cell activation.
Contact
IPO
Employees
Officers
The intrinsic value of one ALEC stock under the Base Case scenario is 6.06 USD.
Compared to the current market price of 5.06 USD, Alector Inc is Undervalued by 17%.